Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk

Published 1 week ago Neutral
Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk
Auto

Related Stocks

AKRO.US Akero Therapeut... LILY34.SA Eli Lilly and C... LLY.MX Eli Lilly and C... NOVO-B.CO Novo Nordisk A/...
Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.

Continue Reading

Afficher les commentaires

More News

Middle East Construction Industry Report 2025-2029: Strategic Planning and Agile Responses are Crucial to Capitalizing on Opportunities

44 minutes ago Positive

Companhia Paranaense de Energia - COPEL reports Q3 results

47 minutes ago Neutral

Form 8.3 - [IDOX PLC - 12 11 2025] - (CGWL)

51 minutes ago Neutral

Latin America Construction Industry Report 2025-2029: Opportunities Across Affordable Housing, Green Building, and Smart Infrastructure Despite Challenges Like Inflation and Regulatory Complexities

51 minutes ago Positive

Kvartalsorientering for 3. kvartal 2025

55 minutes ago Neutral